이화여자대학교 의료원 logo
항생제
Ceftolozane/Tazobactam

Ceftolozane/Tazobactam

제한된

High
N/A

Spectrum Of Activity

General Spectrum of Activity
​

General Information

  • In patients with documented multi-drug resistant (MDR) Pseudomonas or CRE organisms
  • Complicated urinary tract infection
  • Hospital acquired pneumonia
  • Ventilator-associated pneumonia
  • Infectious disease of abdomen, Complicated disease, in combination with metronidazole
  • Pyelonephritis

Improvement in signs and symptoms of infection are indicative of efficacy.

Monitor patients with changing renal function; CrCl at least daily.

Consider monitoring renal function on elderly patients.

Common

  • Fever
  • Headache
  • Diarrhea
  • Nausea

Serious

  • Clostridium difficile colitis
  • Clostridium difficile diarrhea
  • Hypersensitivity reaction
  • Intracranial hemorrhage
  • Renal impairment
  • Cholera vaccine - reduced immune response to the cholera vaccine
  • Probenecid - increased risk of elevated tazobactam serum concentrations

Antimicrobial Class: Cephalosporin, Penicillinase inhibitor

Pregnancy Category: B

Average serum half life: 1.9-4 hours (Ceftolozane), 0.7-3 hours (Tazobactam)

Urine penetration: Therapeutic

Lung penetration: Therapeutic

Precautions:

  • Increased risk of adverse effects in patients with moderate or severe renal impairment and those with ESRD on hemodialysis; monitoring recommended and dose adjustments required.

  • Decreased efficacy has been reported in patients with baseline creatinine clearance of 30-50 mL/min; monitoring recommended.

  • Infectious Diseases consult required for use (intensivists can order empirically in the ICU, if known MDR organism until ID can be consulted).

  • Should be reserved for patients with little or no other treatment alternatives.

Attribution: Antimicrobial information adapted from Sault Area Hospital